Genesee Valley Trust Co buys $1,040,223 stake in PAREXEL International Corporation (PRXL)

PAREXEL International Corporation (PRXL) : Genesee Valley Trust Co scooped up 5,387 additional shares in PAREXEL International Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 12, 2016. The investment management firm now holds a total of 15,043 shares of PAREXEL International Corporation which is valued at $1,040,223.PAREXEL International Corporation makes up approximately 0.67% of Genesee Valley Trust Co’s portfolio.

Other Hedge Funds, Including , Weaver C. Barksdale Associates reduced its stake in PRXL by selling 5 shares or 3.25% in the most recent quarter. The Hedge Fund company now holds 149 shares of PRXL which is valued at $10,303. PAREXEL International Corporation makes up approx 0.02% of Weaver C. Barksdale Associates’s portfolio.Oregon Public Employees Retirement Fund boosted its stake in PRXL in the latest quarter, The investment management firm added 364 additional shares and now holds a total of 18,337 shares of PAREXEL International Corporation which is valued at $1,290,925. PAREXEL International Corporation makes up approx 0.03% of Oregon Public Employees Retirement Fund’s portfolio. Advisory Services Network added PRXL to its portfolio by purchasing 728 company shares during the most recent quarter which is valued at $50,137. PAREXEL International Corporation makes up approx 0.01% of Advisory Services Network’s portfolio.Bnp Paribas Arbitrage Sa reduced its stake in PRXL by selling 14,279 shares or 60.12% in the most recent quarter. The Hedge Fund company now holds 9,470 shares of PRXL which is valued at $646,233.

PAREXEL International Corporation closed down -1.25 points or -1.78% at $69.15 with 4,95,668 shares getting traded on Tuesday. Post opening the session at $70.33, the shares hit an intraday low of $68.495 and an intraday high of $70.33 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, PAREXEL International Corporation reported $0.94 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $0.93. The company had revenue of $538.60 million for the quarter, compared to analysts expectations of $532.59 million. The company’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.79 EPS.

Many Wall Street Analysts have commented on PAREXEL International Corporation. Shares were Downgraded by UBS on Sep 6, 2016 to ” Neutral” and Lowered the Price Target to $ 76 from a previous price target of $82 .

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company which provides a range of expertise in clinical research clinical logistics medical communications consulting commercialization and advanced technology products and services to the pharmaceutical biotechnology and medical device industries across the world. The Company operates through three segments: Clinical Research Services PAREXEL Consulting Services and PAREXEL Informatics. Its product and service offerings include clinical trials management data management epidemiology health economics/outcomes research pharmacovigilance medical communications clinical pharmacology patient recruitment clinical supply and drug logistics post-marketing surveillance medical imaging services electronic data capture systems clinical trial management systems Web-based portals and other product development tools and services.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

PAREXEL International Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on PAREXEL International Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.